Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28112949 | 0.83 | NPC1 (0.33) | KDM4ENPC1ALDH1A1RAB9AROCK2 | |
| SCHEMBL28084904 | 0.79 | TDP2 (0.34) | ROCK2ROCK1CDC42BPB | |
| SCHEMBL30792004 | 0.79 | GOT1 (0.46) | NPY5RGOT1PRMT5WDR77GRM5 | |
| SCHEMBL1456807 | 0.79 | GOT1 (0.46) | NPY5RGOT1PRMT5WDR77GRM5 | |
| SCHEMBL29442588 | 0.79 | GOT1 (0.46) | NPY5RGOT1PRMT5WDR77GRM5 | |
| SCHEMBL1673128 | 0.76 | — | — | |
| SCHEMBL399535 | 0.75 | — | — | |
| SCHEMBL2458453 | 0.73 | CCR1 (0.41) | KDM4EALDH1A1LMNATP53HPGD | |
| SCHEMBL29429423 | 0.72 | KDM4E (0.61) | KDM4ENPC1ALDH1A1LMNATP53 | |
| SCHEMBL252441 | 0.72 | KDM4E (0.61) | KDM4ENPC1ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3193881-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014089364-A1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089364-A1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-8063052-B2 | Wound healing | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100099622-A1 | WOUND HEALING | SYSTAGENIX WOUND MANAGEMENT (US), INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090170910-A1 | WOUND HEALING | KCI USA, INC. | 2009-07-02 | — | — | US | disclosed |
| EP-1786409-A1 | WOUND HEALING | ETHICON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006028836-A1 | WOUND HEALING | ETHICON, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| JP-2005022972-A | 4-(4-PYRIDAZINYL)PYRAZOLE DERIVATIVE | TEIKOKU HORMONE MFG CO LTD | 2005-01-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099622-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | NPY5R 2586/4885GOT1 2875/4885PRMT5 1881/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | NPY5R 4867/4885GOT1 1953/4885PRMT5 982/4885 |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | NPY5R 3561/4885GOT1 1930/4885PRMT5 54/4885 |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | NPY5R 4714/4885GOT1 937/4885PRMT5 78/4885 |
| US-20090170910-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | NPY5R 2586/4885GOT1 2875/4885PRMT5 1881/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | NPY5R 4867/4885GOT1 1953/4885PRMT5 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.